Rimonabant and progression of atherosclerosis in obese persons.
Dora
José Miguel
JM
Scheffel
Rafael Selbach
RS
D019440:Anti-Obesity Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000000981:diagnostic imaging / Q000517:prevention & control*; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy*; D032984:Ethics, Research; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D012107:Research Design; D000077285:Rimonabant; D014463:Ultrasonography
D019440:Anti-Obesity Agents; D010880:Piperidines; D010919:Placebos; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant